A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Masitinib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 05 Jun 2019 According to an AB science media release, the final read-out for the study is expected in 2020.
- 30 May 2019 According to an AB Science media release, data from this trial will be presented at the company webcast on 5 June 2019.
- 03 Dec 2018 Planned End Date changed from 31 Dec 2021 to 1 Sep 2020.